December 13, 2010 07:53 ET

Adeona Pharmaceuticals' Robust Pipleine Is the Focus of Emerging Science Research Report

LOS ANGELES, CA--(Marketwire - December 13, 2010) - BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has issued a report on Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN)

With a diverse clinical program looking for new treatments in several different and key central nervous system disorders, Adeona Pharmaceuticals, Inc. has great potential and some of the company's programs look quite likely move into a commercial deal similar to the one the Ann Arbor-based drug development firm locked up for $17.5 million deal with Swedish drug maker Meda, earlier this year.

"The drugs are extremely exciting," says James Kuo, chairman and CFO of Adeona Pharmaceuticals. "They address the needs of large pharma."

Adeona Pharmaceuticals has five drugs in various stages of development and hopes to form another similar corporate partnership or two this year. It's too bad their depressed stock price doesn't reflect the progress they are making in the clinic and at their laboratory. 

Adeona Pharmaceuticals is developing innovative medicines for the treatment of serious Central Nervous System (CNS) disorders. Their primary strategy is to license product candidates that have demonstrated a certain level of clinical efficacy and develop them to a stage that results in a significant commercial collaboration.

BioMedReports sees this penny stock pick as a low-risk, long-term reward investment candidate with a robust pipeline that includes product candidates in spaces that represent big markets and unmet needs: a prescription medical food for Alzheimer's disease, and four drugs for multiple sclerosis, fibromyalgia, age-related macular degeneration and rheumatoid arthritis.

Read the full report:

Biotech investors interested in seeing more details about these stories and accessing the complete database of clinical trials and upcoming FDA decisions can access that information here:

About BioMedReports.Com is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies in the healthcare sector of the markets.

Contact Information

  • Media Contacts Only:
    Mary Davila
    Assistant Editor
    e-mail: Email Contact
    Tel: +1 323 472 4480
    Fax: +1 888 210 3556